CSF N-glycoproteomics for early diagnosis in Alzheimer's disease

Journal of Proteomics

Volumn 131, Issue , 2016, Pages 29-37

  Palmigiano, Angelo ^a   Barone, Rita ^a,b   Sturiale, Luisa ^a   Sanfilippo, Cristina ^c   Bua, Rosaria Ornella ^a   Romeo, Donata Agata ^a   Messina, Angela ^a   Capuana, Maria Luisa ^c   Maci, Tiziana ^c   Le Pira, Francesco ^c   Zappia, Mario ^c   Garozzo, Domenico ^a  

^a CNR   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

Author keywords

Alzheimer's disease; Bisected glycans; Early diagnosis; MGAT3; Mild cognitive impairment; N glycomics

Indexed keywords

BETA SECRETASE; GLYCOSYLTRANSFERASE; PROTEOME; BIOLOGICAL MARKER; GLYCOPROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; GLYCOPROTEOMICS; HUMAN; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MILD COGNITIVE IMPAIRMENT; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN GLYCOSYLATION; PROTEIN STRUCTURE; PROTEOMICS; SIALYLATION; TANDEM MASS SPECTROMETRY; GENE EXPRESSION PROFILING; MASS SPECTROMETRY; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

AGED; ALZHEIMER DISEASE; BIOMARKERS; EARLY DIAGNOSIS; FEMALE; GENE EXPRESSION PROFILING; GLYCOPROTEINS; HUMANS; MALE; MASS SPECTROMETRY; PROTEOME; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84948800238     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2015.10.006     Document Type: Article

References (27)

1. Reitz C., Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem. Pharmacol. 2014, 88:640-651.
2. Villemagne V.L., Burnham S., Bourgeat P., Brown B., Ellis K.A., Salvado O., et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013, 12:357-367.
3. Kowalska A. Genetic aspects of amyloid β-protein fibrillogenesis in Alzheimer's disease. Folia Neuropathol. 2004, 42:235-237.
4. Stanley P., Schachter H., Taniguchi N. Essentials of Glycobiology 2009, 8:101-114. Spring Harbor Laboratory Press, New York. A. Varki, R.D. Cummings, J.D. Esko, H.H. Freeze, P. Stanley, C.R. Bertozzi (Eds.).
5. Hoffmann A., Nimtz M., Getzlaff R., Conradt H.S. 'Brain-type' N-glycosylation of asialo-transferrin from human cerebrospinal fluid. FEBS Lett. 1995, 359:164-168.
6. Barone R., Sturiale L., Palmigiano A., Zappia M., Garozzo D. Glycomics of pediatric and adulthood diseases of the central nervous system. J. Proteome 2012, 75(17):5123-5139.
7. Schachter H. Biosynthetic controls that determine the branching and microheterogeneity of protein-bound oligosaccharides. Biochem. Cell Biol. 1986, 64:163-181.
8. Akasaka-Manya K., Manya H., Sakurai Y., Wojczyk B.S., Kozutsumi Y., Saito Y., et al. Protective effect of N-glycan bisecting GlcNAc residues on β-amyloid production in Alzheimer's disease. Glycobiology 2010, 20:99-106.
9. Avagyan H., Goldenson B., Tse E., Masoumi A., Porter V., Wiedau-Pazos M., et al. Immune blood biomarkers of Alzheimer disease patients. J. Neuroimmunol. 2009, 210:67-72.
10. Ikeda Y., Ihara H., Tsukamoto H., Gu J., Taniguchi N. Mannosyl (Beta-1,4-)-Glycoprotein Beta-1,4-N-Acetylglucosaminyltransferase (MGAT3); β1,4-N-Acetylglucosaminyltransferase III (GnT-III, GlcNAcT-III). Handbook of Glycosyltransferase and Related Genes 2014, Springer, Japan. N. Taniguchi (Ed.).
11. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984, 34:939-944.
12. Albert M.S., DeKosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C., et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:270-279.
13. Sturiale L., Barone R., Garozzo D. The impact of mass spectrometry in the diagnosis of congenital disorders of glycosylation. J. Inherit. Metab. Dis. 2011, 34:891-899.
14. Ciucanu I., Kerek F. A simple and rapid method for the permethylation of carbohydrates. Carbohydr. Res. 1984, 131:209-217.
15. Royle L.I., Campbell M.P., Radcliffe C.M., White D.M., Harvey D.J., Abrahams J.L., et al. HPLC-based analysis of serum N-glycans on a 96-well plate platform with dedicated database software. Anal. Biochem. 2008, 376:1-12.
16. Papac D.I., Wong A., Jones A.J. Analysis of acidic oligosaccharides and glycopeptides by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Anal. Chem. 1996, 68:3215-3223.
17. Ceroni A., Maass K., Geyer H., Geyer R., Dell A., Haslam S.M. GlycoWorkbench: a tool for the computer-assisted annotation of mass spectra of glycans. J. Proteome Res. 2008, 7:1650-1659.
18. Schedin-Weiss S., Winblad B., Tjernberg L.O. The role of protein glycosylation in Alzheimer disease. FEBS J. 2014, 28:46-62.
19. Fiala M., Liu P.T., Espinosa-Jeffrey A., Rosenthal M.J., Bernard G., Ringman J.M., et al. Innate immunity and transcription of MGAT-III and toll-like receptors in Alzheimer's disease patients are improved by bisdemethoxycurcumin. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:12849-12854.
20. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297(5580):353-356.
21. Mawuenyega K.G., Sigurdson W., Ovod V., Munsell L., Kasten T., Morris J.C., et al. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 2010, 330:1774.
22. Cole S.L., Vassar R. The Alzheimer's disease β-secretase enzyme, BACE 1. Mol. Neurodegener. 2007, 2:22.
23. Charlwood J., Dingwall C., Matico R., Hussain I., Johanson K., Moore S., et al. Characterization of the glycosylation profiles of Alzheimer's beta-secretase protein asp-2 expressed in a variety of cell lines. J. Biol. Chem. 2001, 276:16739-16748.
24. Verheijen J.H., Huisman L.G., van Lent N., Neumann U., Paganetti P., Hack C.E., et al. Detection of a soluble form of BACE-1 in human cerebrospinal fluid by a sensitive activity assay. Clin. Chem. 2006, 52:1168-1174.
25. Kizuka Y., Kitazume S., Fujinawa R., Saito T., Iwata N., Saito T., et al. An aberrant sugar modification of BACE1 blocks its lysosomal targeting in Alzheimer's disease. EMBO Mol. Med. 2015, 7:175-189.
26. Giuffrida M.L., Caraci F., Pignataro B., Cataldo S., De Bona P., Bruno V., et al. Beta-amyloid monomers are neuroprotective. J. Neurosci. 2009, 29:10582-10587.
27. Selkoe D.J. Preventing Alzheimer's disease. Science 2012, 337:1488-1492.